<DOC>
	<DOC>NCT01324297</DOC>
	<brief_summary>The purpose of this study is to gather normative data from healthy adults and to determine a sensitive and specific cut-off value for responders and non-responders to the Niacin Skin Flush Test in a sample of first episode psychosis patients.</brief_summary>
	<brief_title>The Topical Niacin Skin Flush Test in First Episode Psychosis</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<criteria>caucasian within twelve months of initial DSM IV TR diagnosis of schizophreniform psychosis, schizophrenia, schizoaffective disorder or psychotic disorder NOS outpatient known allergy to study compound (methyl nicotinate, vitamin B3, niacin) skin conditions (e.g., dermatitis, psoriasis, eczema) diagnosis or treatment for medical conditions that may affect normal vascular tone (e.g., diabetes, vasculitis, chronic hypertension, etc.) Use of antiinflammatory, antibiotic, or antihistamine medications within one month prior to study entry Use of supplements like Omega 3 fatty acids within 3 months prior to study entry Use of vitamin or nutritional supplement containing a dose of niacin/nicotinic acid above 50 mg/day at study entry</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Diagnostic Techniques and Procedures</keyword>
	<keyword>Sensitivity and Specificity</keyword>
	<keyword>Skin Tests</keyword>
	<keyword>Biological Markers</keyword>
</DOC>